Loss of MED12 promotes the transition of a mesenchymal phenotype, which is accompanied by chemotherapy resistance in colon cancer patients and resistance to the tyrosinase inhibitor gefitinib in lung cancer. Here, MED12 is linked to malignant colon neoplasm.